| 序号 | 专利名 | 申请号 | 申请日 | 公开（公告）号 | 公开（公告）日 | 发明人 |
|---|---|---|---|---|---|---|
| 101 | METHODS FOR THE SYNTHESIS OF CHIRAL KYNURENINE COMPOUNDS | EP14770640 | 2014-03-14 | EP2970097A4 | 2016-11-16 | ABELE STEFAN; LAUE KLAUS; BREITENMOSER ROLAND A |
| Provided are methods for synthesizing compounds, including chiral kynurenine compounds. The methods are suitable for large-scale manufacture and produce the chiral kynurenines compounds in high chemical purity and high chiral purity. | ||||||
| 102 | HYALURONIC ACID DERIVATIVES CONTAINING GROUPS ABLE TO RELEASE NO | EP08773646.8 | 2008-06-25 | EP2173775B1 | 2012-11-28 | RENIER, Davide; D'ESTE, Matteo |
| 103 | HYALURONIC ACID DERIVATIVES CONTAINING GROUPS ABLE TO RELEASE NO | EP08773646.8 | 2008-06-25 | EP2173775A1 | 2010-04-14 | RENIER, Davide; D'ESTE, Matteo |
| Disclosed are hyaluronic acid derivatives functionalised with S-nitrosothiol groups of the general formula: wherein HA indicates hyaluronic acid and G indicates a suitable spacer. | ||||||
| 104 | S-NITROSOTHIOLS CONTAINING COMPOSITIONS AND THE USE OF SUCH COMPOSITIONS FOR THE TREATMENT OF FATTY LIVER DISEASES, OBESITY AND OTHER DISEASES ASSOCIATED WITH THE METABOLIC SYNDROME AND THE USE OF SUCH COMPOSITIONS | EP07719267.2 | 2007-04-20 | EP2010164A1 | 2009-01-07 | GANZAROLLI DE OLIVEIRA, Marcelo; PEREIRA DE SOUZA, Gabriela Freitas; GANZAROLLI DE OLIVEIRA, Fernando; SOUZA DE OLIVEIRA, Claudio Pinto Marques; VELLOSO, Licio Augosto |
| The present invention refers to pharmaceutical compositions containing S-nitrosothiols as active principle. The referred compositions are intended for the treatment of the fatty liver disease and other diseases associated with the metabolic syndrome. The composition is administered either orally or rectally. | ||||||
| 105 | ALPHA-AMIDES OF(L)-AMINO ACIDS AS FRAGRANCE PRECURSORS | EP98961953.1 | 1998-12-07 | EP1052968B1 | 2007-12-05 | SLIFE, Charles, W.; LANEY, Judith, Wolfe; GOLDMAN, Virginia, Streusand |
| Disclosed are α-amides of L-amino acids that produce fragrance or attenuate or mask malodor. In particular, glutamine and asparagine amides can be used in the invention. Such α-amides of L-amino acids are useful for generating pleasant fragrances or attenuating or masking malodor upon cleavage of the α-amides of L-amino acids by bacteria in axillae. The α-amides of L-amino acids can be incorporated into skin treatment compositions and personal care products, such as deodorants, body sprays and antiperspirants, and used in methods for producing fragrance or attenuating or masking malodor. | ||||||
| 106 | NITRONE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME AND METHODS FOR TREATING INFLAMMATION AND NEUROPATHIC PAIN | EP03773284 | 2003-10-15 | EP1578717A4 | 2006-08-09 | KHAN M AMIN; UPASANI RAVINDRA B; WOOD PAUL L |
| 107 | NOVEL MMP-2/MMP-9 INHIBITORS | EP01944167 | 2001-05-24 | EP1283823A4 | 2005-07-27 | ARNOLD ANNE ROMANIC; CHENERA BALAN; GIRARD GERALD R; WEINSTOCK JOSEPH |
| Novel MMP-2/MMP-9 inhibitors and methods of using them are provided. | ||||||
| 108 | PRODUCTION OF D,L-ASPARTIC ACID | EP97927843 | 1997-05-30 | EP0934248A4 | 2000-02-02 | MAZO GRIGORY YA; MAZO JACOB; VALLINO BARNEY JR; ROSS ROBERT J |
| The present invention is directed to a method for the production of D,L-aspartic acid. The method comprises reacting an unsatured dicarboxylic acid or anhydride such as maleic acid, fumaric acid, maleic anhydride or mixtures thereof with excess aqueous ammonia at an elevated temperature and pressure for a time sufficient to produce diammonium D,L aspartate. The diammonium D,L aspartate is then neutralized to D,L-aspartic acid; excess unreacted ammonia and various by-products may be recycled and re-used in the method, thereby minimizing waste and cost; i.e. the process is useful for a continuous production process which may be represented conveniently as a schematic block diagram wherein a pressurized reactor (10) receives a reactant admixture from feed tank (12), the reactants being fed subsequently to flash vessel (14) and then precipitator (16) where D,L-aspartic acid is produced upon neutralization, with dicarboxylic acid salts being recovered in a centrifuge (18) and dried in a drier (20). The D,L-aspartic acid may subsequently be used to make polyaspartic acid. | ||||||
| 109 | Non-linear optical device | EP87300731.4 | 1987-01-28 | EP0234751A2 | 1987-09-02 | Allen, Simon; Gordon, Paul Francis; Morley, John Oswald |
Optical elements comprising a non-centrosymmetric compound comprising an electron donor and an electron acceptor linked by a conjugated bridging group, in which the electron acceptor is a nitroso groups, in which element the molecules of the compound are aligned so that the element has a net non-centrosymmetry, a method for their preparation, optical devices comprising such elements, and some of the compounds. |
||||||
| 110 | METHODS FOR THE SYNTHESIS OF CHIRAL KYNURENINE COMPOUNDS | PCT/US2014/027694 | 2014-03-14 | WO2014152752A1 | 2014-09-25 | ABELE, Stefan; LAUE, Klaus; BREITENMOSER, Roland, A. |
Provided are methods for synthesizing compounds, including chiral kynurenine compounds. The methods are suitable for large-scale manufacture and produce the chiral kynurenines compounds in high chemical purity and high chiral purity. |
||||||
| 111 | HYALURONIC ACID DERIVATIVES CONTAINING GROUPS ABLE TO RELEASE NO | PCT/EP2008/005140 | 2008-06-25 | WO2009003624A1 | 2009-01-08 | RENIER, Davide; D'ESTE, Matteo |
Disclosed are hyaluronic acid derivatives functionalised with S-nitrosothiol groups of the general formula: wherein HA indicates hyaluronic acid and G indicates a suitable spacer. |
||||||
| 112 | S-NITROSOTHIOLS CONTAINING COMPOSITIONS FOR THE TREATMENT OF FATTY LIVER DISEASES, OBESITY AND OTHER DISEASES ASSOCIATED WITH THE METABOLIC SYNDROME AND THE USE OF SUCH COMPOSITIONS | PCT/BR2007000099 | 2007-04-20 | WO2007121545A8 | 2008-02-14 | GANZAROLLI DE OLIVEIRA MARCELO; PEREIRA DE SOUZA GABRIELA FREI; GANZAROLLI DE OLIVEIRA FERNAND; SOUZA DE OLIVEIRA CLAUDIO PINT; VELLOSO LICIO AUGOSTO |
| The present invention refers to pharmaceutical compositions containing S-nitrosothiols as active principle. The referred compositions are intended for the treatment of the fatty liver disease and other diseases associated with the metabolic syndrome. The composition is administered either orally or rectally. | ||||||
| 113 | PROCESS FOR SYNTHESIZING L-Y-METHYLENE GLUTAMIC ACID AND ANALOGS | PCT/US0333236 | 2003-10-22 | WO2004039314A3 | 2004-12-09 | KOCHAT HARRY; CHEN XINGHAI; WU YE; HUANG QIULI; WANG JIANYAN; GERUSZ VINCENT |
| A process for synthesizing substantially enantiomerically pure L-amino acids, particularly L- -methylene glutamic acid, and esters and salts thereof. The process includes the derivatization of (2S)-pyroglutamic acid, and the decyclization of the resulting derivative to form the desired end product. | ||||||
| 114 | NITRONE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME AND METHODS FOR TREATING INFLAMMATION AND NEUROPATHIC PAIN | PCT/US0332883 | 2003-10-15 | WO2004034999A3 | 2004-06-17 | KHAN M AMIN; UPASANI RAVINDRA B; WOOD PAUL L |
| Disclosed are nitrone compounds and pharmaceutical compositions containing such compounds. The nitrone compounds have one to six additional carbons bridging between the nitrone functionality and the nitrone aryl ring. The disclosed compositions are useful as therapeutics for inflammation-related conditions and analgesia in mammals, such as arthritis, and for neuropathic pain and traumatic injuries such as traumatic brain injury and acute spinal cord injury. The invention accordingly extends to the use of the compounds and compositions for the stated treatments, and as appropriate, to the use of the compounds for the preparation of pharmaceutical compositions for such treatments. | ||||||
| 115 | C-NITROSO COMPOUNDS AND USE THEREOF | PCT/US0127734 | 2001-09-27 | WO0234705A3 | 2002-07-11 | STAMLER JONATHAN S; TOONE ERIC J |
| A C-nitroso compound having a molecular weight ranging from 225 to 1,000 (from 225 to 600 for oral administration) on a monomeric basis wherein a nitroso group is attached to a tertiary carbon, which is obtained by nitrosylation of a carbon acid having a pKa less than about 25, is useful as an NO donor. When the compound is obtained from a carbon acid with a pKa less than about 10, it provides vascular relaxing effect when used at micromolar concentrations and this activity is potentiated by glutathione to be obtained at nanomolar concentrations. When the compound is obtained from a carbon acid with a pKa ranging from about 15 to 20, vascular relaxing effect is obtained at nanomolar concentrations without glutathione. In another embodiment, a biocompatible polymer incorporates a C-nitroso moiety. | ||||||
| 116 | NOVEL MMP-2/MMP-9 INHIBITORS | PCT/US2001/016867 | 2001-05-24 | WO01090047A1 | 2001-11-29 | |
| Novel MMP-2/MMP-9 inhibitors and methods of using them are provided. | ||||||
| 117 | alpha -AMIDES OF L-AMINO ACIDS AS FRAGRANCE PRECURSORS | PCT/US1998/025906 | 1998-12-07 | WO99030679A1 | 1999-06-24 | |
| Disclosed are alpha -amides of L-amino acids that produce fragrance or attenuate or mask malodor. In particular, threonine amides, glycine amides, serine amides, and alanine amides can be used in the invention. Such alpha -amides of L-amino acids are useful for generating pleasant fragrances or attenuating or masking malodor upon cleavage of the alpha -amides of L-amino acids by bacteria in axillae. The alpha -amides of L-amino acids can be incorporated into skin treatment compositions and personal care products, such as deodorants, body sprays and antiperspirants, and used in methods for producing fragrance or attenuating or masking malodor. | ||||||
| 118 | 신규한 비페닐 옥심 에스테르 유도체 화합물 및 이를 포함하는 광중합 개시제 및 포토레지스트 조성물 | KR1020150134920 | 2015-09-23 | KR1020170035697A | 2017-03-31 | 오천림; 이재훈; 이득락; 이민선; 이원중; 조용일 |
| 본발명은신규한비페닐옥심에스테르유도체화합물및 이를포함하는광중합개시제및 포토레지스트조성물에관한것으로, 상세하게는본 발명에따른비페닐옥심에스테르유도체화합물은하기화학식 1로표시되는것을특징으로한다. [화학식 1] | ||||||
| 119 | 플루오렌 구조를 갖는 신규한 광개시제 및 이를 포함하는 반응성 액정 조성물 및 감광성 조성물 | KR1020130066691 | 2013-06-11 | KR101567837B1 | 2015-11-11 | 구자성; 차재령; 오소연; 김효진; 전윤태; 도윤선; 이기우; 최광식 |
| 본발명은플루오렌구조를갖는신규한광개시제및 이를포함하는반응성액정조성물및 감광성조성물에관한것으로, UV 광원에대한장파장흡수율이높아내부경화에우수한반응성을보이며, 광감도특성이우수하여반응전환율이높아반응성액정조성물및 감광성조성물에서상용성이우수한플루오렌구조를갖는신규한광개시제및 이를포함하는반응성액정조성물및 감광성조성물에관한것이다.본발명의플루오렌구조를갖는신규한광개시제하기 [일반식]으로표시되는것을특징으로한다.[일반식]상기 [일반식]에서 R, R는서로독립적으로수소(이때, R및 R가모두수소는아니다.), 하기 [화학식 1] 내지 [화학식 9]으로표시되는광개시그룹중에서어느하나선택되며, R, R는서로독립적으로수소, 불소, 탄소수가 1-6인직쇄형또는분지형의알킬이다. | ||||||
| 120 | ＨＩＶ 인티그레이즈 억제제 | KR1020047009018 | 2002-12-06 | KR1020040065251A | 2004-07-21 | 워커,마이클,에이.; 밴빌,자끄; 르밀라드,로저; 프라몬돈,세르지 |
| 본 발명은 하기 화학식의 화합물, 또는 상기 화합물의 토토머, 또는 그의 약제학적으로 허용가능한 염, 용매화물 또는 그의 전구약물을 투여하여 HIV 인티그레이즈의 억제, 및 AIDS 또는 ARC를 치료하는 것에 관한 것이다: 상기식에서, R 1 , R 2 및 B 1 는 본원에 정의한 바와 같다. | ||||||
QQ群二维码
意见反馈
意见反馈